Answered: Explain, the mechanism of chaperone…

Science

Biology

Explain, the mechanism of chaperone mediated autophagy.

Biology 2e

2nd Edition

ISBN:9781947172517

Author:Matthew Douglas, Jung Choi, Mary Ann Clark

Publisher:Matthew Douglas, Jung Choi, Mary Ann Clark

Chapter17: Biotechnology And Genomics

Section: Chapter Questions

Problem 22CTQ: Describe the precess of Southern blotting

See similar textbooks

Related questions

Q: In polarized MDCK cells, proteins X and Y normally are located to the apical plasma membrane domain,…

A: The clathrin-coated vesicles are responsible for the endocytosis and internalization of the AP-2…

Q: Identify the ligand that bind to uniprotkb-P39086, the type of allostery, and describe the general…

A: P39086 is an ID for a protein GRIK1_HUMAN that belongs to Homosapiens. It is a protein of 918 amino…

Q: ''The chemical carcinogen dimethylbenz[a]anthra-cene (DMBA) must be an extraordinarily specific…

A: Abnormal growth of skin cells when exposed to sunlight causes skin cancer. They are originated from…

Q: Antibodies that bind with high affinity to some viral surface proteins require heavy chain CDR3…

A: Introduction: An antibody is a glycoprotein produced by the plasma cells in response to an allergen…

Q: Attenuation affects anabolic pathways, whereas repression affects either anabolic or catabolic…

A: Transcription is the process in which the DNA sequence of a gene is copied to create a molecule of…

Q: Can you develop a siRNA-based technology to treat COVID-19? If so, please provide the details on the…

A: YES,according to me this insight seams to be reasonable. siRNA or small interfering RNA is a non…

Q: 21:14 +4G KB/S LTED 41 96 09.00 Vo Microsoft Word - Assignment 02.docx Assignment 02 1. Groups of…

A: “Since you have asked multiple question, we will solve the first question for you. If youwant any…

Q: The carboxy terminus of the p53 protein acts as an allosteric regulator of sequence-specific DNA…

A: General structure of p53 protein

Q: both noncoding and coding). a. Which types of SNPs affect protein production or function for the…

A: Single Nucleotide Polymorphisms are the specific differences in the chain of DNA in different…

Q: Pinpointing a disease gene requires a combination of approaches. Mutations in the XIAP gene are…

A: X-linked lymphoproliferative disease (XLPD) is an extremely rare inherited immunodeficiency…

Q: 10 SCNSA-SCN10A CDKN1A HAND1 VTI1A SYT1 MYOCD :

A: Answer :- In the 2019 GWAS study focused on identifying loci impacting the risk of prolonged QRS…

Q: 7 8 9 9 10 11 1 TONSL vs Primary log2FPKM Raw counts 2 foldchange log2FC PValue KTB_103_pr…

A: Method: Identification of Differentially Expressed Genes (DEGs) in Breast Cancer Using RNA-Seq and…

Q: Describe how ES cells are used to generate knockoutmice.

A: Knockout mice is a genetically modified mice in which the researchers have inactivated or knocked…

Q: 2. Transaription of gene X is controlled by transcription factor A (TFA). Gene X is only transcribed…

A: Genes are segments present in DNA that are transcribed to mRNA that codes for a specific protein.…

Q: Discuss the two mechanisms that result in the termination of transcription - How do they differ and…

A: Transcription is a process in which RNA is synthesized with the help of the template strand of DNA…

Q: Why is it important that NEB express I^q cells do not have endonuclease? What could happen if they…

A: A cell is a mass of the cytoplasm that is bound externally by a membrane called as the cell…

Q: E23. In the Western blot shown here, proteins were isolated from red blood cells and muscle cells…

A: Western blot we use to perform to detect the presence of a specific protein by using a specific…

Concept explainers

Defense Mechanism

Circumstances influence and compel people to behave in a certain way. One such behavior is a defense mechanism. It is employed by people to escape from unpleasant circumstances, thoughts and actions. Defense mechanisms are, thus, psychological strategies that help to avert and avoid unwanted feelings such as guilt or shame and situations such as threat and danger.

Question

Pls do not copy paste

Explain, the mechanism of chaperone mediated autophagy.

Expert Solution

This question has been solved!

Explore an expertly crafted, step-by-step solution for a thorough understanding of key concepts.

SEE SOLUTION Check out a sample Q&A here

Step 1

VIEW

Step 2

VIEW

Step by step

Solved in 2 steps

SEE SOLUTION Check out a sample Q&A here

Knowledge Booster

Learn more about

Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, biology and related others by exploring similar questions and additional content below.

Similar questions

The Adaptive Immune Response Is a Specific Defense Against Infection In cystic fibrosis gene therapy, scientists propose the use of viral vectors to deliver normal genes to cells in the lungs. What immunological risks are involved in this procedure?
Describe how RBPs can prevent miRNAs from degrading an RNA molecule.
Who Owns Your Genome? John Moore, an engineer working on the Alaska oil pipeline, was diagnosed in the mid-1970s with a rare and fatal form of cancer known as hairy cell leukemia. This disease causes overproduction of one type of white blood cell known as a T lymphocyte. Moore went to the UCLA Medical Center for treatment and was examined by Dr. David Golde, who recommended that Moores spleen be removed in an attempt to slow down or stop the cancer. For the next 8 years, John Moore returned to UCLA for checkups. Unknown to Moore, Dr. Golde and his research assistant applied for and received a patent on a cell line and products of that cell line derived from Moores spleen. The cell line, named Mo, produced a protein that stimulates the growth of two types of blood cells that are important in identifying and killing cancer cells. Arrangements were made with Genetics Institute, a small start-up company, and then Sandoz Pharmaceuticals, to develop the cell line and produce the growth-stimulating protein. Moore found out about the cell line and its related patents and filed suit to claim ownership of his cells and asked for a share of the profits derived from the sale of the cells or products from the cells. Eventually, the case went through three courts, and in July 1990n years after the case beganthe California Supreme Court ruled that patients such as John Moore do not have property rights over any cells or tissues removed from their bodies that are used later to develop drugs or other commercial products. This case was the first in the nation to establish a legal precedent for the commercial development and use of human tissue. The National Organ Transplant Act of 1984 prevents the sale of human organs. Current laws allow the sale of human tissues and cells but do not define ownership interests of donors. Questions originally raised in the Moore case remain largely unresolved in laws and public policy. These questions are being raised in many other cases as well. Who owns fetal and adult stem-cell lines established from donors, and who has ownership of and a commercial interest in diagnostic tests developed through cell and tissue donations by affected individuals? Who benefits from new genetic technologies based on molecules, cells, or tissues contributed by patients? Are these financial, medical, and ethical benefits being distributed fairly? What can be done to ensure that risks and benefits are distributed in an equitable manner? Gaps between technology, laws, and public policy developed with the advent of recombinant DNA technology in the 1970s, and in the intervening decades, those gaps have not been closed. These controversies are likely to continue as new developments in technology continue to outpace social consensus about their use. Should the physicians at UCLA have told Mr. Moore that his cells and its products were being commercially developed?
Who Owns Your Genome? John Moore, an engineer working on the Alaska oil pipeline, was diagnosed in the mid-1970s with a rare and fatal form of cancer known as hairy cell leukemia. This disease causes overproduction of one type of white blood cell known as a T lymphocyte. Moore went to the UCLA Medical Center for treatment and was examined by Dr. David Golde, who recommended that Moores spleen be removed in an attempt to slow down or stop the cancer. For the next 8 years, John Moore returned to UCLA for checkups. Unknown to Moore, Dr. Golde and his research assistant applied for and received a patent on a cell line and products of that cell line derived from Moores spleen. The cell line, named Mo, produced a protein that stimulates the growth of two types of blood cells that are important in identifying and killing cancer cells. Arrangements were made with Genetics Institute, a small start-up company, and then Sandoz Pharmaceuticals, to develop the cell line and produce the growth-stimulating protein. Moore found out about the cell line and its related patents and filed suit to claim ownership of his cells and asked for a share of the profits derived from the sale of the cells or products from the cells. Eventually, the case went through three courts, and in July 1990n years after the case beganthe California Supreme Court ruled that patients such as John Moore do not have property rights over any cells or tissues removed from their bodies that are used later to develop drugs or other commercial products. This case was the first in the nation to establish a legal precedent for the commercial development and use of human tissue. The National Organ Transplant Act of 1984 prevents the sale of human organs. Current laws allow the sale of human tissues and cells but do not define ownership interests of donors. Questions originally raised in the Moore case remain largely unresolved in laws and public policy. These questions are being raised in many other cases as well. Who owns fetal and adult stem-cell lines established from donors, and who has ownership of and a commercial interest in diagnostic tests developed through cell and tissue donations by affected individuals? Who benefits from new genetic technologies based on molecules, cells, or tissues contributed by patients? Are these financial, medical, and ethical benefits being distributed fairly? What can be done to ensure that risks and benefits are distributed in an equitable manner? Gaps between technology, laws, and public policy developed with the advent of recombinant DNA technology in the 1970s, and in the intervening decades, those gaps have not been closed. These controversies are likely to continue as new developments in technology continue to outpace social consensus about their use. Do you think that donors or patients who provide cells and/or tissues should retain ownership of their body parts or should share in any financial benefits that might derive from their use in research or commercial applications?
The prospect of using gene therapy to alleviate genetic conditions is still a vision of the future. Gene therapy for adenosine deaminase deficiency has proved to be quite promising, but many obstacles remain to be overcome. Currently, the correction of human genetic defects is done using retroviruses as vectors. For this purpose, viral genes are removed from the retroviral genome, creating a vector capable of transferring human structural genes into sites on human chromosomes within target-tissue cells. Do you see any potential problems with inserting pieces of a retroviral genome into humans? If so, are there ways to combat or prevent these problems?
How does NF-kB induce gene expression? A small, hydrophobic ligand binds to NF-kB, activating it. Phosphorylation of the inhibitor Ik-B dissociates the complex between it and NF- kB, and allows NF-kB to enter the nucleus and stimulate transcription. NF-kB is phosphorylated and is then free to enter the nucleus and bind DNA. NF-kB is a kinase that phosphorylates a transcription factor that binds DNA and promotes protein production.
Equalizing the Expression of X Chromosome Genes in Males and Females Males have only one X chromosome and therefore only one copy of all genes on the X chromosome. Each gene is directly expressed, thus providing the basis of hemizygosity in males. Females have two X chromosomes, but one is always inactivated. Therefore, females, like males, have only one functional copy of all the genes on the X chromosome. Again, each gene must be directly expressed. Why, then, are females not considered hemizygous, and why are they not afflicted with sex-linked recessive diseases as often as males are?
Describe how transcription in prokaryotic cells can be altered by external stimulation such as excess lactose in the environment.
Discuss Concepts In a mutant strain of E. coli, the CAP protein is unable to combine with its target region of the lac operon. How would you expect the mutation to affect transcription when cells of this strain are subjected to the following conditions? Lactose and glucose are both available. Lactose is available but glucose is not. Both lactose and glucose are unavailable.
INTERPRET DATA Develop a simple hypothesis that would explain the behavior of each of the following types of mutants in E. coli. Mutant a: The map position of this mutation is in the trp operon. The mutant cells are constitutive; that is, they produce all the enzymes coded for by the trp operon, even if large amounts of tryptophan are present in the growth medium. Mutant b: The map position of this mutation is in the trp operon. The mutant cells do not produce any enzymes coded for by the trp operon under any conditions. Mutant c: The map position of this mutation is some distance from the trp operon. The mutant cells are constitutive; that is, they produce all the enzymes coded for by the trp operon, even if the growth medium contains large amounts of tryptophan.
Discuss Concepts Why do you suppose cells evolved internal response mechanisms using molecules that bind GTP instead of ATP?
Prions are responsible for variant Creutzfeldt Jakob Disease, which has resulted in over 100 human deaths in Great Britain during the last 10 years. How do humans contract this disease?